Brenntag (BNTG.F) Earnings Call Presentation

Financial Performance & Strategy - Brenntag reported Q2 2025 sales of EUR 38694 million, a decrease of 41% compared to the previous year, adjusted for FX[146] - Operating Gross Profit for Q2 2025 was EUR 9743 million, down by 19% year-over-year, FX adjusted[146] - Q2 2025 Operating EBITA reached EUR 2464 million, a 139% decrease compared to the previous year, FX adjusted[146] - The company's cost-out program contributed approximately EUR 30 million in savings during Q2 2025 compared to Q2 2024[145] - Brenntag maintains a capital allocation framework that includes annual Capex of EUR 300-400 million and M&A spending of EUR 400-500 million, implying a ~3% annual Operating EBITA growth contribution[17] Business Divisions - Brenntag Specialties reported FY 2024 Operating Gross Profit of EUR 12 billion and Operating EBITA of EUR 447 million[7] - Brenntag Essentials reported FY 2024 Operating Gross Profit of EUR 29 billion and Operating EBITA of EUR 781 million[7] - Brenntag Essentials aims for a 5-7% CAGR in Operating EBITA by FY27E, driven by portfolio shifts, volume growth, inflation normalization, and operational excellence[74] - Brenntag Specialties targets a 7-9% CAGR in Operating EBITA by FY27E through price and margin management, cost-out initiatives, portfolio management, and value-added services[100] Market Dynamics & Growth - The chemical distribution market is structurally expanding, with a mid-term underlying sales growth of 3-5% per annum[36] - Brenntag aims for a total CAGR of 10-12%, with organic CAGR contributing 7-9% by 2027[20] - M&A remains a core part of Brenntag's growth strategy, with approximately EUR 39 billion spent on over 100 acquisitions since IPO, contributing around 3% annual Operating EBITA growth[6, 14]